NBI BIOSCIENCES PRIVATE LIMITED

In their own words

Overview: NBI Biosciences (MSME: DL08D0019679 ) is an 18 month young startup, positioned at the cusp of healthcare and biotechnology. Its business seeks to create global patented medicinal formulations, from plant material, and offer them to large populations around the world that suffer from various ailments and conditions. In a nutshell, NBI is focused on attaining multiple patents with 25 years of exclusive rights, under the global patent regime, and building revenue from operating channels that are driven by market dynamics. Over these 18 months, the business has been “seed” funded to about Rs.3 CR by Atul Kumar who continues to head the business as its MD. NBI Biosciences operates with a vision of “… Benefiting The health and happiness of all life on the planet…” To achieve this vision we are well advanced to create medicinal formulation patents for human conditions that are chronic in nature for which these synthesised chemical medicines do not offer a cure. The monetisation potential of every patent is exceptional particularly given the structural advantages available to NBI, namely, the global shift towards plant-based formulations by roughly 8% YOY, And the very low participation in the low participation of India in the world trade at roughly 3% which is mostly at the commodity end of the business value chain. Our revenue model expects to generate, over a three year period, a net revenue of Rs.1000 CR With a market share capture of 1%. The risk mitigation of over six patents currently underway is high and this list of products will only grow. The operating strategy at NBI Biosciences is focused on conserving cash and therefore has adopted a stringent asset light policy. As an example, we have not invested 10’s of crores in buying hard assets such as laboratory devices and instead use new operating ideas to achieve our research goals at a fraction of the cost. Within this same operating strategy we expect to create a manufacturing portfolio with partners who we expect will invest in the manufacturing in a profitable Way. Of course, NBI will retain certain elements of protective manufacturing under its own direct control for reasons of confidentiality and IP protection at a fraction of the cost that may be required to delve into a full manufacturing programme. We Seek a funding of about Rs.27 CR and expect to invest this in three different areas, leadership and innovation, protective manufacturing and growing these ideas at a global level beginning with the US. Our current leadership teams are aligned to the above described business model and strategy and consist of experts as well as advisers in areas such as India’s biodiversity, US investments, technical marketing expertise and others. Team details are provided for your review in the attachment. Our product strategy is described above and we wish to add that all patents plan for a rolling period of 12 months for their creation. This rolling nature of our product strategy requires a single time funding mechanism after which the internal revenues cover any potential Cost. We will be delighted to share details of all the individual patents once an NDA has been signed with potential investors.

Written by the company on its public Startup India profile. Not verified by us.